Axcella Health Inc. (AXLA)
Dec 29, 2023 - AXLA was delisted (reason: company dissolved)
0.4009
0.00 (0.00%)
Inactive · Last trade price on Dec 29, 2023

Company Description

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States.

The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence.

The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016.

Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Axcella Health Inc.
Axcella Health logo
CountryMA
Founded2008
IPO DateMay 9, 2019
IndustryBiotechnology
SectorHealthcare
Employees11
CEOCraig R. Jalbert CIRA

Contact Details

Address:
840 Memorial Drive, Third Floor
Cambridge, Massachusetts 02139
Phone617-868-0949
Websiteaxcellahealth.com

Stock Details

Ticker SymbolAXLA
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001633070
CUSIP Number05454B105
ISIN NumberUS05454B2043
SIC Code2836

Key Executives

NamePosition
William R. Hinshaw Jr.President, Chief Executive Officer and Director
Dr. Alison D. Schecter M.D.President of Strategy and Operations
David R. Epstein B.Sc., M.B.A.Consultant
Laurent ChardonnetConsultant
Robert W. CraneSenior Vice President and Chief Financial Officer
Dr. Paul Fehlner J.D., Ph.D.Senior Vice President, Chief Legal Officer and Corporate Secretary
Virginia R. DeanSenior Vice President and Chief People Officer
Dr. Larry BellGlobal Head of Regulatory Affairs and Pharmacovigilance and Senior Vice President
Dr. Margaret James Koziel M.D.Senior Vice President and Chief Medical Officer
Dan KirbySenior Vice President of Strategic Operations

Latest SEC Filings

DateTypeTitle
Dec 22, 20238-KCurrent Report
Dec 19, 20238-KCurrent Report
Dec 4, 20238-KCurrent Report
Nov 17, 20238-KCurrent Report
Nov 17, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Nov 17, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Nov 17, 2023DEF 14AOther definitive proxy statements
Nov 9, 20238-KCurrent Report
Nov 6, 2023PRE 14AOther preliminary proxy statements
Nov 1, 20238-KCurrent Report